Literature DB >> 33217349

Socio-Economic Burden of Myocardial Infarction Among Cancer Patients.

Avirup Guha1, Amit Kumar Dey2, Sadeer Al-Kindi3, P Elliott Miller4, Arjun K Ghosh5, Amitava Banerjee6, Juan Lopez-Mattei7, Nihar R Desai8, Brijesh Patel9, Guilherme H Oliveira10, Marcos de Lima11, Michael Fradley12, Daniel Addison13.   

Abstract

Cancer patients face a higher risk of future myocardial infarction (MI), even after completion of anticancer therapies. MI is a critical source of physical and financial stress in noncancer patients, but its impacts associated with cancer patients also saddled with the worry (stress) of potential reoccurrence is unknown. Therefore, we aimed to quantify MI's stress and financial burden after surviving cancer and compare to those never diagnosed with cancer. Utilizing cross-sectional national survey data from 2013 to 2018 derived from publicly available United States datasets, the National Health Interview Survey , and economic data from the National Inpatient Sample , we compared the socio-economic outcomes in those with MI by cancer-status. We adjusted for social, demographic, and clinical factors. Overall, 19,504 (10.2%) of the 189,836 National Health Interview Survey responders reported having cancer for more than 1 year. There was an increased prevalence of MI in cancer survivors compared with noncancer patients (8.8% vs 3.2%, p <0.001). MI was associated with increased financial worry, food insecurity, and financial burden of medical bills (p <0.001, respectively); however, concurrent cancer did not seem to be an effect modifier (p >0.05). There was no difference in annual residual family income by cancer status; however, 3 lowest deciles of residual income representing 21.1% cancer-survivor with MI had a residual income of <$9,000. MI continues to represent an immense source of financial and perceived stress. In conclusion, although cancer patients face a higher risk of subsequent MI, this does not appear to advance their reported stress significantly.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33217349      PMCID: PMC8406452          DOI: 10.1016/j.amjcard.2020.11.005

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

1.  Strategies used and challenges faced by a breast cancer patient navigator in an urban underserved community.

Authors:  Jeanne M Ferrante; Justine Wu; Barbara Dicicco-Bloom
Journal:  J Natl Med Assoc       Date:  2011-08       Impact factor: 1.798

2.  Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2019. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2018-04-17

3.  Changes in Health Insurance Coverage Associated With the Affordable Care Act Among Adults With and Without a Cancer History: Population-based National Estimates.

Authors:  Amy J Davidoff; Gery P Guy; Xin Hu; Felisa Gonzales; Xuesong Han; Zhiyuan Zheng; Helen Parsons; Donatus U Ekwueme; Ahmedin Jemal
Journal:  Med Care       Date:  2018-03       Impact factor: 2.983

4.  Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Robin M Lally; Terry S Langbaum; Allison L McDonough; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-10       Impact factor: 11.908

5.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Authors:  Jean-Charles Soria; Daniel S W Tan; Rita Chiari; Yi-Long Wu; Luis Paz-Ares; Juergen Wolf; Sarayut L Geater; Sergey Orlov; Diego Cortinovis; Chong-Jen Yu; Maximillian Hochmair; Alexis B Cortot; Chun-Ming Tsai; Denis Moro-Sibilot; Rosario G Campelo; Tracey McCulloch; Paramita Sen; Margaret Dugan; Serafino Pantano; Fabrice Branle; Cristian Massacesi; Gilberto de Castro
Journal:  Lancet       Date:  2017-01-24       Impact factor: 79.321

Review 6.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

7.  Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.

Authors:  Michaela A Dinan; Yanhong Li; Yinghong Zhang; Suzanne B Stewart; Lesley H Curtis; Daniel J George; Shelby D Reed
Journal:  Clin Genitourin Cancer       Date:  2015-08-06       Impact factor: 2.872

8.  How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives.

Authors:  S Yousuf Zafar; Lee N Newcomer; Justin McCarthy; Shelley Fuld Nasso; Leonard B Saltz
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

9.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

10.  Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients.

Authors:  Jieling Elaine Chen; Vivian Weiqun Lou; Hong Jian; Zhen Zhou; Meiqiong Yan; Jingfen Zhu; Guohong Li; Yaping He
Journal:  Support Care Cancer       Date:  2017-11-06       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.